A 24-year-old man with a history of type 1 diabetes mellitus is brought to the emergency department with altered mental status, vomiting, and diffuse abdominal pain. His blood pressure is 90/60 mmHg, heart rate is 125/min, and respiratory rate is 28/min with deep, rapid breaths. Laboratory studies reveal a blood glucose of 650 mg/dL, arterial pH of 7.12, serum bicarbonate of 10 mEq/L, and a high anion gap. Urinalysis is strongly positive for ketones. Arrange the following steps in the management of this patient's condition in the most appropriate chronological order.
- 1Administer a rapid intravenous bolus of 0.9% normal saline
- 2Verify serum potassium concentration is > 3.3 mEq/L
- 3Initiate a continuous intravenous infusion of regular insulin
- 4Add 5% dextrose to the maintenance intravenous fluids
- 5Administer subcutaneous long-acting basal insulin
Answer
The correct sequence is: Administer 0.9% normal saline -> Verify potassium > 3.3 mEq/L -> Initiate IV regular insulin -> Add 5% dextrose to fluids -> Administer subcutaneous basal insulin.
The management of diabetic ketoacidosis follows a strict, step-wise algorithm designed to safely correct volume depletion, hyperglycemia, and ketoacidosis while preventing fatal electrolyte shifts. First, severe fluid deficit is addressed with isotonic 0.9% normal saline. Second, because insulin drives potassium intracellularly, one must verify the serum potassium is greater than 3.3 mEq/L to prevent arrhythmias. Third, an intravenous insulin infusion is started to halt ketone production. Fourth, as blood glucose falls below 200-250 mg/dL, 5% dextrose is added to the fluids so insulin can continue running to close the anion gap without causing hypoglycemia. Finally, once the anion gap is closed, the patient is transitioned to subcutaneous insulin.
Step-by-Step Solution
Key Concept
The sequential management of diabetic ketoacidosis (DKA) prioritizes volume resuscitation, followed by potassium assessment, continuous insulin administration, glucose supplementation as levels fall, and finally transition to subcutaneous insulin.